Prednisone raw material characterization and formulation development by Toehwé, Leonardo Henrique et al.
Braz. J. Pharm. Sci. 2017;53(4):e00088 Page 1 / 14
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902017000400088
A
rt
ic
le
*Correspondence: H. V. A. Rocha. Laboratório de Sistemas Farmacêuticos 
Avançados, Farmanguinhos/Fiocruz. Av. Comandante Guaranys, 447 – Jacarepa-
guá – 22775-903 - Rio de Janeiro – RJ – Brasil. E-mail: helvecio.far@gmail.com
Prednisone raw material characterization and formulation 
development
Leonardo Henrique Toehwé1,2, Livia Deris Prado3, Helvécio Vinícius Antunes Rocha2,3,*
¹Laboratório Químico-Farmacêutico da Aeronáutica, Rio de Janeiro, Brasil, ²Mestrado Profissional em Gestão, Pesquisa 
e Desenvolvimento na Indústria Farmacêutica, Farmanguinhos/Fiocruz, Rio de Janeiro, Brasil, ³Laboratório de Sistemas 
Farmacêuticos Avançados, Farmanguinhos/Fiocruz, Rio de Janeiro, Brasil
Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy 
because they are easily administered, have high productivity and relatively low cost and provide a more 
stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage 
form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference 
product and three test formulations were evaluated using stability testing. During the study, prednisone 
tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers 
were characterized with respect to their physical and physicochemical properties. The results showed 
that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical 
equivalence throughout all the stability study. Notably, both samples of API prednisone were of the 
same crystal form, and any phase transition that occurred during the study could not be attributed to 
dissolution variation during stability. 
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INTRODUCTION
Prednisone is a glucocorticoid that is extensively 
used in clinical practice (Romanholi, Salgado, 2007). Its 
therapeutic use is recommended for a variety of acute 
and chronic diseases, such as arthritis, hepatitis, allergic 
diseases, asthma, leprosy, and numerous other autoimmune 
and inflammatory diseases (Kaiser, Kley, 2002).
In Brazil, there are several industries commercialising 
prednisone in the form of oral immediate release tablets. 
Currently, Meticorten® is the reference product for these 
formulations at concentrations of 5, 20 and 50 mg (Anvisa, 
2013).
Prednisone has the molecular formula C21H25O5 and 
a molar mass of 358.43 g/mol (Farmacopeia Brasileira, 
2010). It is an odourless white or almost white powder 
that melts at 233 °C with decomposition and may exhibit 
polymorphism. At room temperature, this drug is poorly 
soluble in methanol, ethanol, chloroform and dioxane, with 
low solubility in water (Farmacopeia Brasileira, 2010). 
Prednisone is a neutral molecule, and its pKa values  are not 
reported in the literature. Its solubility in water is 0.133 mg/
mL at 25 °C, and three values  for the partition coefficient 
(Log P) are reported in the literature: 1.46, 1.47 and 1.6 
(Vogt et al., 2007; Passion, Gouveia, Morais, 2012).
Commercially active pharmaceutical ingredient (API) 
prednisone is an anhydrous, monohydrate or prednisone 
acetate salt. However, only the anhydrous and monohydrate 
forms are referenced in the Brazilian, European and United 
States Pharmacopoeia (European Pharmacopoeia, 2010; 
Farmacopeia Brasileira, 2010; USP, 2012).
According to parameters adopted by the International 
Pharmaceutical Federation (FIP), prednisone is classified 
as a class I drug of the Biopharmaceutical Classification 
System (BCS) and is highly soluble and permeable 
(Storpirtis et al., 2009). However, Vogt et al. (2007) 
argued in a review study that in the absence of conclusive 
data on permeability, absorption and solubility under the 
conditions recommended by the BCS, this drug does not 
have a classification defined in relation to the BCS.
Full characterization of the drug is an essential step 
for a formulation development study given that variations 
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in characteristics, such as crystal structure, particle size, 
and fluidity, can significantly impact on bioavailability 
parameters, processability and stability (Fung, Ng, 2003; 
Iacocca, Burcham, Hilden, 2010).
Another issue that is rarely evaluated is related to the 
monitoring of the dissolution properties of formulations 
during stability. Although there is a regulatory prerogative 
requiring the completion of the dissolution test for the 
stability study, there is no requirement for an analysis of 
the dissolution profile. Few authors have demonstrated the 
manner in which it makes a difference (Ochi et al., 2016; 
Payghan et al., 2012; Vidal et al., 2010).
The objective of the present study was to characterize 
the active pharmaceutical ingredient (API) prednisone 
and the formulation of a solid dosage form (tablet) for 
registration as a generic medicine and to evaluate the 
dissolution stability of this formulation. 
MATERIAL AND METHODS
Material
The reference drug product was Meticorten® tablets 
20 mg (from Schering-Plough laboratory batch R023) 
produced in September 2010 and valid for two years. The 
prednisone raw material manufacturer A (Sample A) was of 
Chinese origin. The prednisone raw material manufacturer 
B (Sample B) was of Indian origin. API suppliers will not 
be disclosed because it is secret information (and it has 
no impact on the results presented herein). The excipients 
were corn starch (Quimica BPAR), croscarmellose sodium 
(Blanver), magnesium stearate (Magnesia), sodium starch 
glycolate (Amishi Drugs and Chemicals Ltd), lactose 
monohydrate (DFE Pharma), sodium lauryl sulfate 
(Stephan Philippines Inc.), mannitol (Shandong Tianli 
Pharmaceutical Co.), polyvinylpyrrolidone K30 (Nanhang 
Industrial Co.), and magnesium silicate (Talmag Pharma-S).
METHODS
Raw material characterization
Differential scanning calorimetry
Analyses were performed using an exploratory 
differential calorimeter model 822e Mettler Toledo. 
Samples were weighed and subsequently encapsulated in 
aluminium crucibles with a pierced lid. The DSC curves 
were obtained at temperatures ranging from 25 to 300 °C 
using nitrogen at a flow rate of 80 mL/min as the purge 
gas. Measurements were performed at the heating rates of 
2.5, 5 and 10 °C/min.
Thermogravimetric analysis (TGA)
T h e  a n a l y s e s  w e r e  p e r f o r m e d  u s i n g  a 
thermogravimetric analyser Model Mettler Toledo 851e. 
Samples of approximately 3.5 mg were weighed and 
encapsulated in open aluminium pans. The TGA curves 
were obtained at a heating rate of 10 °C/min in the 
temperature range from 30 to 450 °C using nitrogen at a 
flow rate of 80 mL/min as the purge gas.
Powder X-ray diffraction
The X-ray diffractometer was operated with a 
potential difference across the tube of 30 kV and 15 
mA. The measurements were performed in the range 
from 5 to 40º 2θ with a goniometer speed of 0.05 °/
sec. The radiation used was CuKα (λ = 1.5418 Å). The 
experimental diffraction patterns were compared with a 
simulated diffraction pattern obtained from the Mercury 
software (Macrae et al., 2008), which was prepared using 
the deposited structure at the Cambridge Crystallographic 
Data Structure Database (CSD) (Allen, 2002).
Fourier transform infrared spectroscopy
The analyses were conducted on a Shimadzu 8000 
FTIR spectrometer Prestige applying infrared spectroscopy 
with Fourier transform (FTIR). Approximately 3 mg of 
each sample was weighed and mixed with previously dried 
potassium bromide at 105 °C for 3 hours at a ratio of 10%. 
Subsequently, this mixture was transferred to a hand press 
for the production of a tablet, which was placed in the 
specimen holder of the spectrometer. The same procedure 
was performed for the chemical reference substances 
(SQR) of the USP and Brazilian Pharmacopoeia. The 
spectra were recorded at 4000-400 cm-1.
Intrinsic dissolution
To determine the intrinsic dissolution, tablets were 
prepared from prednisone samples (manufacturers A and 
B). The samples were subjected to different levels of 
compressive forces. Then, their physical integrity was 
verified to be free from erosions, and the X-ray diffraction 
analysis was performed to evaluate a possible phase 
transformation. The pressure selected for the experiment 
was 1200 psi because the inserts exhibited no erosion and 
the drug showed no phase transition under this condition. 
Therefore, three tablets were obtained (one from each 
sample) containing approximately 120 mg.
Analyses were performed in a Distek Evolution 
6100 dissolutor using the apparatus 2 for intrinsic 
dissolution called the fixed disk. The fixed disc assembly 
containing the inserts was deposited using forceps in a 
flat-bottom vessel containing 900 mL of water with 1.2% 
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sodium lauryl sulfate (w/v). During the experiment, 10-
mL aliquots were collected without medium replacement 
at 5, 10, 15, 20, 30, 45 and 60 minutes. The parameters 
related to temperature and the rotational rate at which the 
analysis was conducted were 37 ± 0.5 °C and 150 rpm, 
respectively. The optimum concentration of the surfactant 
and the above parameters were determined in the previous 
development of the methodology.
The analyses were performed in triplicate, and the 
amount of active drug released was obtained by reading the 
absorbance in a UV spectrophotometer at a wavelength of 
242 nm. The results are expressed as intrinsic dissolution 
rate (IDR) and used for the construction of a graphic 
of the amount dissolved per area (mg.cm-2) versus time 
(minutes).
Powder dissolution
To determine powder dissolution behaviour by 
dispersion, 20 mg of each sample (A and B) was added to 
the dissolution vessel containing 900 mL of purified water. 
The analysis was performed in triplicate with the same 
parameters used for the dissolution test for prednisone 
tablets described in the Brazilian Pharmacopoeia 
(Farmacopeia Brasileira, 2010) (temperature of 37 ± 0.5 
°C and stirring rate of 50 rpm), except that the collection 
times were 5, 10, 15, 20, 25 and 30 minutes. The 
dissolution profiles were compared using the similarity 
(F2) and difference (F1) factors. 
Scanning electron microscopy
Photomicrographs were obtained using a Quanta 
400 scanning electron microscope (FEI). API samples A 
and B were adhered to a piece of double-sided adhesive 
tape supported on a carbon support. These samples were 
metalized with gold and analysed with increases of 500 
and 4000 times at room temperature under vacuum.
Solubility
To determine the solubility of the samples (A and B), 
an excess of powder was added to the dissolution vessels 
containing 500 mL of the following three different media: 
hydrochloric acid buffer pH 1.2, phosphate buffer pH 6.8 
and distilled water pH 5.5. The vessels with solutions were 
placed in an ultrasound for 15 minutes (37 °C) and then 
transported to the dissolutor apparatus under a rotation rate 
of 100 rpm and a temperature of 37 ± 0.5 °C for 24 hours. 
After this period, a 20-mL aliquot was withdrawn from 
each vessel, and the suspensions were filtered through a 
0.45-µm membrane, diluted and then analysed by UV-Vis 
spectrophotometry at a wavelength of 242 nm (Okumu, 
Dimaso, Löbenberg, 2009; Wei, Löbernberg, 2006). Each 
experiment was performed in triplicate, and the pH of each 
sample was monitored during the experiment.
Evaluation of the API according to pharmacopoeic 
criteria 
The assay for prednisone samples A and B was 
performed using ultraviolet absorption spectrophotometry 
according to the method (A) described in the Brazilian 
Pharmacopoeia 5th edition (Farmacopeia Brasileira, 2010). 
Formulation
The process used in the manufacturing of the pilot 
batches was wet granulation based on high shear with an 
aqueous-based solution followed by fluidized bed drying. 
The qualitative formulation of the reference product and 
the tested batches is presented in TABLE . Three batches 
were produced: P0020020910, MEST01 and MEST02. All 
of the batches followed the same manufacturing process. 
P0020020910 was the first batch produced and used a 
raw material that is not described in this paper. This batch 
was used in the bioequivalence study. Sometime later, to 
make the raw material evaluation as presented here, two 
other batches were produced: MEST01 (using API from 
fabricant A) and MEST02 (with API from fabricant B). 
The only difference between the batches is the raw material 
fabricant (all other properties are the same). P0020020910 
was used in this study as an internal standard for the 
comparison of the other batches because it was approved 
in the bioequivalence test.
Tablet characterization
Tablet evaluation according to pharmacopoeic tests
Average weight tests,  hardness,  fr iabil i ty, 
disintegration time, assay and humidity followed the 
recommendations in the Brazilian Pharmacopoeia 5th 
edition (Farmacopeia Brasileira, 2010).
Dissolution profile
The dissolution profiles of the test and reference 
products were determined from the measurement of 
prednisone released at intervals of 5, 10, 15, 20, 25 and 30 
minutes. The apparatus 2 (paddle) was used with a stirring 
rate of 50 rpm. The dissolution medium used was 900 mL 
of distilled water at 37 °C. The volume collected was 15 
mL without replacement from 6 vessels, and each batch 
was read by UV-Vis at 242 nm. An SR8 PLUS Hanson 
Research dissolutor was used. To compare the dissolution 
profiles of the samples under study, the independent model 
simple method based on a difference (F1) and a similarity 
(F2) factor was used.
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Stability study
Samples from all batches were stored in a controlled 
climate room with a temperature of 30 °C ± 2 °C and a 
relative humidity (RH) of 75% ± 5%. Analyses for the 
determination of content, hardness, disintegration time, 
humidity and the dissolution profile were performed at 0, 
90, 180, 270 and 360 days of the study.
RESULTS AND DISCUSSION
Prednisone API characterization
Thermogravimetric analysis (TGA)
From the TG curves (Figure 1) obtained for samples 
A and B, at zero and 360 days, both samples were thermally 
stable up to approximately 261 °C. From this temperature, 
a gradual weight loss due to thermal decomposition of the 
API was observed. This result excludes the possibility 
of said samples when treating the monohydrate form 
or solvate with chloroform, as reported in the literature, 
because the samples studied exhibited no mass loss until 
the beginning of their thermal decomposition (Kuhnert-
Bramdstätter, Gasser, 1971; Mesley, Johnson, 1965).
Differential scanning calorimetry (DSC)
The calorimetric profiles presented in Figure 2 
indicate the possibility that two different crystalline 
forms exist because the melting peaks displayed different 
temperatures. The results of the tests at 2.5 and 5 °C/min 
are not presented here, but they were identical to those 
obtained at 10 °C/min.
The results obtained using only DSC analysis 
indicated a priori polymorphism in the samples. These data 
however contradict those obtained by X-ray diffraction.
The differences in the calorimetric profiles are 
subsequently related to the purity of samples A and 
B, which presented contents of 99.7% and 98.5%, 
respectively. The presence of small amounts of impurities 
in a substance may decrease the melting point and 
increase its melting range (Donnelly et al., 1990). In 
the literature, authors have also used DSC to determine 
the purity of a given substance (Ferguson et al., 2000; 
Schnitzler et al., 2001). However, this technique should 
not be used for this purpose when the analyte decomposes 
during its fusion (Dooren, Muller, 1984), such as for 
prednisone (Farmacopeia Brasileira, 2010). Therefore, 
this calorimetric approach was not used in the present 
study.
Powder X-ray diffraction
Despite the question raised by DSC regarding the 
presence of polymorphism in the samples, characterization 
by X-ray diffraction (Figure 3) confirmed the presence of 
the same crystalline phase in samples A and B. The peaks 
in the diffraction pattern are the same in both samples. 
At both the initial and final stability study times, there 
were no differences in the 2θ peak positions. The study 
also demonstrated that compared with an XRD pattern 
simulated from crystallographic data of an anhydrous 
crystalline form of prednisone deposited in the CSD 
(Allen, 2002), the samples had the same crystalline phase 
as that described here. Therefore, it is concluded that 
during the study period and at the temperature and relative 
humidity conditions used for storage, no crystalline phase 
transition was observed in the samples.
Infrared spectroscopy
The infrared absorpt ion spectrum resul ts 
demonstrated that at time zero, prednisone samples A 
and B alone exhibited absorption maxima at the same 
wavelength and the same relative intensities as those 
observed in the spectrum of samples of the USP and 
Brazilian Pharmacopoeia standards (Figure 4). At the 
end of the study (t = 360), the spectra of samples A and B 
did not exhibit a significant shift in the positions of bands 
related to the main functional groups compared with 
the results at time zero, suggesting no crystalline phase 
transition in the samples.
Intrinsic dissolution 
The intrinsic dissolution rate (IDR) is an important 
tool to evaluate the differences between polymorphs and 
solvates, particularly when there is a small amount of 
sample available (Qiu, Chen, Zhang, 2009). This type 
of dissolution evaluates the API in an isolated form, i.e., 
TABLE I - Excipients present in the reference medicine and pilot 
batches
Excipients R023 Test batches
Starch (corn) X X
Croscarmellose sodium X
Magnesium stearate X X
Sodium starch glycolate X
Lactose monohydrate X
Sodium lauryl sulfate X
Mannitol X
Povidone (PVP) X X
Magnesium silicate X
All batches were packaged in PVC blisters, as informed by the 
reference product manufacturer.
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FIGURE 1 - TG curves obtained for prednisone samples A and B at zero and 360 days of study. 
FIGURE 2 - DSC curves of samples A and B at a heating rate of 10 °C/min.
without the presence of excipients (Gibson, 2009). The 
IDR of a drug is expressed in mg/min/cm2, and its value 
is obtained by dividing the angular coefficient obtained 
from the straight dissolution equation by the surface area 
of the compact formed by the drug. The results obtained 
for samples A and B are presented in Figure 5.
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As shown in Figure 5, the intrinsic dissolution 
profiles revealed a pronounced linear behaviour because 
both samples had a coefficient of determination that was 
greater than 0.99. With this linearity, it was concluded that 
there was no phase transition during the analysis and that 
the sink condition was also maintained during all times 
considered in the analysis.
Samples A (6.71 mg/min/cm2) and B (6.73 mg/
min/cm2) exhibited similar dissolution profiles and IDR. 
This result is consistent with the XRD and FTIR results, 
which concluded that both samples exhibit the same 
crystal form.
Similar to the results obtained in the solubility test 
to classify the samples as highly soluble according to the 
BCS, a study correlating the IDR of 15 drugs performed 
by Yu et al. (2004) considered that an IDR greater than 
0.1 mg.min-1.cm-2 indicates high solubility, and drugs with 
lower values exhibit low solubility. Thus, according to 
this study, both samples are classified as highly soluble. 
Zakeri-Milani et al. (2009) mentioned approximately 0.58, 
0.63, and 3.45 mg/min/cm2 for furosemide (solubility of 
1.474 mg/mL), ketoprofen (2.12 mg/mL), and atenolol 
(16.87 mg/mL), respectively. Dezani et al. (2013) reported 
that the zidovudine (solubility of ~20 mg/mL) IDR is 
0.75 mg/min/cm2. 
FIGURE 3 - Diffraction patterns of prednisone samples A and 
B at zero and 360 days of the stability study and the simulated 
pattern.
FIGURE 4 - Fourier transform infrared spectroscopy (FTIR) of prednisone samples A and B at zero and 360 days of the stability 
study and the USP (USP St) and Brazilian Pharmacopoeia (FB St) standards.
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Powder dissolution
The results of the powder dissolution for both 
samples are presented in Figure 6. Samples A and B had 
a mean dissolution of 87.7% and 85.1% at 30 minutes, 
respectively. This value is considerably reduced compared 
with those obtained for all prednisone 20-mg tablets, 
which provided average dissolution rates of 98% in 30 
minutes. This discrepancy in the results may have occurred 
during the analysis because part of the active drug floated 
on the surface of the medium and/or attached to the 
apparatus (paddle), forming a cluster. Therefore, part of 
the active added mass did not come into contact with the 
environment and did not undergo the dissolution process. 
This observation is not so common in tablet dissolution 
because the excipients in this case can enhance powder 
wettability and lower static properties verified in the 
powder alone.
Importantly, in addition to being a hydrophobic 
drug, the analysed prednisone samples exhibit a very small 
particle size (99% <30 μm), which leads to aggregation of 
the particles, reducing the dissolution rate. 
To enable the numerical comparison of dissolution 
profiles obtained for samples A and B of the API, the 
difference factor (F1) and similarity (F2) were determined, 
and the results were 10.03 and 58.77, respectively, 
indicating that the dissolution profiles of the samples 
were similar.
Solubility (saturation)
The solubility, understood here as saturation, is 
a parameter that expresses a state of thermodynamic 
equilibrium between the solvent and solute. This 
equilibrium is dependent on a number of experimental 
conditions, such as temperature (Qiu, Chen, Zhang, 2009). 
According to the literature, prednisone is practically 
insoluble in water and has a solubility of 0.133 mg/mL at 
25 °C (Vogt et al., 2007).
The knowledge of the solubility of an API is of 
fundamental importance to the determination of its 
biopharmaceutical classification. In accordance with the 
BCS, the solubility should be determined at 37 °C and 
in an aqueous medium with different pH values. Table II 
presents the solubility values experimentally obtained 
according to the BCS for prednisone samples A and B.
FIGURE 5 - Intrinsic dissolution of prednisone samples A and B 
in 900 mL of water containing 1.2% sodium lauryl sulfate using 
apparatus 2 at 150 rpm.
FIGURE 6 - Comparison between powder dissolution profiles 
of prednisone samples A (circle) and B (triangle).
TABLE II - Solubility values experimentally obtained according to the BCS for prednisone samples A and B
Media
Solubility (mg/mL) at 37 ºC Volume (mL) necessary to solubilize 50 mg
Sample A Sample B Sample A Sample B
HCl buffer, pH 1.2 4.48 4.51 11.03 11.08
Water, pH 5.5 4.53 4.54 11.04 11.01
Phosphate buffer, pH 6.8 4.55 4.57 10.98 10.94
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Samples A and B exhibited a solubil i ty of 
approximately 4.5 mg/mL at 37 °C for all tested pH 
values. This result is consistent with the information 
obtained from the literature that ranks prednisone as a 
neutral molecule; therefore, changes in pH do not affect 
its solubility (Vogt et al., 2007).
Based on these results, both samples can be 
classified as highly soluble, and the volume of medium 
required to dissolve 50 mg of prednisone (a larger dose 
available for domestic dosage) was approximately 11 mL 
at all pH values  tested, which is significantly less than the 
250 mL recommended by the BCS.
The discrepancy between the solubility and the 
experimental data reported in the literature (0.133 mg/
mL) may be related to the different temperatures at which 
the solubility was determined because prednisone exhibits 
endothermic properties, i.e., its solubility increases with 
increasing temperature (Vogt et al., 2007).
Scanning electron microscopy
The photomicrographs obtained for both samples 
A and B (Figure 7) reveal irregular and small particles 
that are mostly smaller than 30 micrometres. Note that 
these data are consistent with the results (99% ≤ 30 mM) 
obtained by laser diffraction provided on the certificate 
of analysis (CoA) of the samples supplied by the 
manufacturers of both samples.
Active pharmaceutical ingredient evaluation using 
pharmacopeic criteria
Samples A and B were approved in all pharmacopeial 
tests. The contents found for the raw materials A and B at 
different time intervals are presented in Table III.
The contents of both samples showed no significant 
variation over the entire course of the study.
Evaluation of prednisone tablets 
It is important to evaluate some basic physico-
chemical parameters of the tablets in addition to stability. 
During the development of drug products, quality control 
of the dosage forms must be evaluated from a variety of 
different aspects (Table IV).
According to the limits recommended by the 
Brazilian Pharmacopoeia 5th edition to assess weight 
change in uncoated tablets, all samples were within the 
established limit. Notably, in general, all lots had a small 
increase in average weight and values for the maximum 
and minimum weights observed. This finding may be 
related to the small increase in moisture that occurred in 
all lots during the stability study.
Regarding disintegration, lots P0020020910, 
MEST01 and MEST02, which were produced with 
the same formulation, presented maximum values of 3 
minutes and 20 seconds.
Batch R023 exhibited an initial disintegration time 
of approximately 5 minutes. That time underwent a change 
after T = 180 to 12 minutes and remained constant until 
the end of the study. This increase may be related to the 
excipient povidone present in the formulation, as this 
polymer can form a film on particles of the granulate 
and consequently the induration of the tablets over time, 
thereby jeopardizing the process of disintegration and 
dissolution (Blok, 2007; Murthy, Guebre-Sellassie, 1993).
The Brazilian Pharmacopoeia 5th edition does not 
recommend tests for moisture in prednisone tablets, but FIGURE 7 - SEM photomicrographs of sample A (1 and 2) and sample B (3 and 4).
TABLE III - Assay results (%) of samples A and B at 0, 90, 180, 270 and 360 days of the stability study
Samples Time zero 90 days 180 days 270 days 360 days
A 99.7 99.8 99.6 99.8 99.6
B 98.5 98.8 98.7 98.6 98.6
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this parameter was evaluated during stability studies to 
assess a possible correlation with the mechanical strength 
test and the dissolution profile of the tablets studied because 
these data directly affect these parameters (Aulton, 2005). 
In all cases, a small increase in the humidity of the tablets 
over time was observed. This pattern was also observed 
TABLE IV - Compilation of the results of pharmacopoeic parameters of the formulations evaluated during the stability study
Parameter
Result
R023 P0020020910 MEST01 MEST02
Average weight (mg)
T = 0 303.4 142.1 143.2 140.7
90 days 303.7 142.3 143.4 140.9
180 days 303.6 143.1 143.6 141.2
270 days 304.1 143.0 143.7 141.3
360 days 304.3 143.4 144.0 141.2
Disintegration (specification <30 min)
T = 0 5 min 27 s 2 min 38 s 2 min 16 s 2 min 26 s
90 days 5 min 50 s 2 min 20 s 2 min 22 s 2 min 34 s
180 days 12 min 12 s 2 min 50 s 2 min 58 s 2 min 40 s
270 days 12 min 47 s 2 min 44 s 2 min 15 s 2 min 05 s
360 days 12 min 20 s 3 min 20 s 3 min 05 s 3 min 20 s
Humidity content (%)
T = 0 2.53 5.71 4.71 4.67
90 days 2.62 5.85 4.78 4.70
180 days 2.75 6.26 4.65 4.73
270 days 2.68 6.32 4.77 4.87
360 days 3.23 6.25 5.20 4.96
Hardness (N) (average ± RSD)
T = 0 57.4 ± 8.7 53.1 ± 8.1 21.6 ± 6.1 33.0 ± 6.5
90 days 60.5 ± 5.1 55.6 ± 10.5 23.4 ± 10.7 33.6 ± 11.3
180 days 64.9 ± 9.5 56.8 ± 5.6 23.9 ± 5.9 35.5 ± 6.7
270 days 65.8 ± 5.6 56.2 ± 7.5 25.2 ± 7.4 38.5 ± 5.9
360 days 66.4 ± 6.8 55.8 ± 5.7 25.7 ± 5.6 38.7 ± 7.3
Friability (specification < 1%)
T = 0 0.42 0.33 0.72 0.58
90 days NR 0.36 0.67 0.43
180 days NR 0.29 0.54 0.49
270 days NR 0.25 0.45 0.33
360 days NR 0.21 0.20 0.24
Assay (specification 90-110%) (average ± RSD)
T = 0 106.7 ± 0.3 100.6 ± 0.4 100.4 ± 0.4 101.7 ± 0.2
90 days 106.0 ± 0.2 100.4 ± 0.2 100.0 ± 0.9 101.2 ± 0.3
180 days 105.9 ± 0.5 100.1 ± 0.4 100.7 ± 0.2 101.3 ± 0.3
270 days 105.7 ± 0.3 100.2 ± 0.7 100.3 ± 8.4 100.7 ± 0.5
360 days 105.8 ± 0.3 99.9 ± 0.2 100.1 ± 0.7 100.4 ± 0.2
NR = not realised
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for the reference drug product, and a humidity variation 
slightly greater than the reference remains for the test drug. 
For a PVC, i.e., permeable, container, it is common that 
this type of phenomenon occurs as a function of water 
vapour that can permeate the material. Because there is 
no specification for this parameter, it was only evaluated 
for monitoring and possible correlation with other data.
According to the Brazilian Pharmacopoeia, the 
hardness test is informative but does have existing approval 
parameters (Farmacopeia Brasileira, 2010). Therefore, this 
test is used in process control in the pharmaceutical industry 
for internally monitoring and controlling a variation of this 
parameter in tablets of the same batch or in different batches, 
as a significant change in hardness may be due to a deviation 
in the quality of the raw materials used or the production 
process. However, the mechanical strength of the tablets 
can also be altered during storage. Such changes can be 
caused by numerous factors, including moisture absorption, 
changes in crystal structure and plastic deformation of 
particles (Aulton, 2005).
The results obtained during the stability study 
indicate a small increase in hardness for all batches. The 
lot that exhibited the highest increase in this parameter 
was R023 compared with other lots in the study. Similar 
to disintegration, the increase in hardness was potentially 
triggered by the association of factors, such as increased 
moisture absorption and the use of povidone in the tablets 
(Blok, 2007; Murthy, Guebre-Sellassie, 1993).
The friability results reveal an increase in the 
mechanical resistance to attrition of the tablets during the 
stability study, which may be associated with the moisture 
absorbed by the tablets. This moisture would lead to the 
formation of solid bridges between particles, increasing 
their resistance (Aulton, 2005). Importantly, the friability 
for the R023 batch was not assessed at all study times due 
to the unavailability of that lot on the market, but it has no 
impact on the statements presented here.
All results of content and uniformity of content are 
approved. However, a certain strangeness was noted in the 
content values  for the reference product. Despite falling in 
the range of approval, these values are well above average, 
tending towards the upper range limit. This type of result 
suggests that one cannot categorically state that there is an 
addition of excess active ingredient during manufacturing, 
a practice known as overage, which is not recommended 
by regulators. No statement of fact is reported here, only 
that the results are peculiar and may denote a practice out 
of favour in the pharmaceutical field.
Dissolution profiles of the tablets
The individual results of the dissolution profiles 
of lots R023, P0020020910, MEST01, and MEST02 at 
zero, 90, 180, 270 and 360 days of the stability study are 
presented in Figure 8. 
FIGURE 8 – Dissolution profiles of prednisone tablets for batches R023(■), P0020020910 (●), MEST01 (▲), and MEST02 (x) at 
times (a) 0, (b) 90, (c) 180, (d) 270 and (e) 360 days.
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The F1 and F2 values, comparative indices used for 
the evaluation of the similarity and difference between 
two dissolution profiles were also calculated to better 
verify the monitoring of lots for stability. The results are 
presented in Table V.
Batch P0020020910 exhibited an average release 
rate that was greater than 85% within 15 minutes for all 
time points in the stability profile, which was maintained 
during the entire study. Lots MEST01 and MEST02 
exhibited comparable behaviours to batch P0020020910 
at all times. Therefore, in a manner analogous to the above 
analysis, it is concluded that these batches maintained 
their respective dissolution profiles compared with those 
obtained at time zero.
Although batch R023 presented an average release 
rate exceeding 85% within 15 minutes and values less 
than 15 for F1 and greater than 50 for F2 at all times of the 
stability study, the results presented in Table 5 and Figure 
24 indicate that this batch underwent a significant change 
in its dissolution profile. This change began at t = 180 and 
remained at t = 270 and t = 360, when an active release 
within five minutes of 7.5%, 6.6% and 6.7%, respectively, 
was observed. These values differ from the percentage 
release rates observed at time t = 0 and t = 90, which were 
29.9% and 28.8%, respectively, within five minutes. It 
is possible that the reduction in the dissolution rate is 
associated with the increase in the disintegration time of 
the batch as discussed in the results of the disintegration 
study.
Comparison of dissolution profiles is a useful 
tool when the behaviour of two drugs must be known 
before conducting a study of relative bioavailability/
bioequivalence or pharmaceutical equivalence to claim 
exemption from such studies or for a possible post-
registration change (Anvisa, 2011; 2010). However, when 
performed during the stability study, this comparison 
enables the evaluation of whether a formulation that has an 
initial dissolution profile equivalent to another formulation 
maintains that status throughout its shelf life.
Importantly, the rate at which a drug is released 
from its dosage form can be a limiting factor in the rate 
of absorption. Thus, a possible variation in this parameter 
during storage can cause a change in the beginning 
intensity or duration of a therapeutic response (Murthy, 
Guebre-Sellassie, 1993).
All batches of 20-mg prednisone tablets submitted 
to the study met the acceptance criteria established in 
the official monograph (Farmacopeia Brasileira, 2010), 
which must have a dissolution rate greater than 80% 
after 30 minutes of the test. According to the current 
Brazilian regulatory perspective, it is not necessary to 
calculate factor F1 or F2 for drugs of high solubility 
and rapid dissolution formulations. Therefore, batches 
P0020020910, MEST01 and MEST02 maintained their 
dissolution profiles equivalent to that of batch of R023 
because these batches exhibited a dissolution that was 
greater than 85% for the first 15 minutes (Anvisa, 2010). 
However, during the study period, the F1 and F2 values 
calculated for lots P0020020910, MEST01 and MEST02 
(Table V) showed a reduction of similarity and an increase 
in the difference between their dissolution profiles 
compared with batch R023. Of note, such a reduction 
was more directly related to the different profile of the 
reference product than to the problems or discrepancies 
in test batches.
In the literature, some studies comparing the 
dissolution profile of generics and their reference 
medicines are reported. Operto and collaborators (2008) 
compared 10 brands of paracetamol tablets produced 
in Argentina. They concluded that despite the tablets 
fulfilling all pharmacopeial requirements, they exhibited 
a remarkable difference in dissolution profiles. Kohler et 
al. (2009) evaluated the dissolution profiles of five generic 
500 mg dipyrone tablets and concluded that none were 
equivalent to the reference drug product.
Similarly, Brum et al. (2012) analysed 8 brands 
of 750-mg paracetamol tablets available in Brazil and 
also found that one of the generic brands did not show 
a dissolution profile equivalent to that of the reference 
product. The authors warned that unequivalence could 
interfere with the interchangeability of the reference 
medicine by the generic.
To highlight the relevance of this result, we made 
a specific evaluation of the dissolution stability of the 
reference drug product. Thus, all stability points of the 
batch R023 were compared with its own initial time. 
This type of evaluation has been reported by Murthy 
and Guebre-Sellassie (1993) as an important tool to 
predict the performance of a tablet during stability and to 
demonstrate whether it retains the same quality during the 
shelf-life. Most regulatory recommendations (as in Brazil) 
exclusively claim the dissolution results for registration 
but not the dissolution profile.
As noted in Table V, based on F1 and F2 values, the 
reference medicine was stable during the first year of the 
stability study. However, F2 was reduced from 95.99 at 90 
days to 50.79 in one year, which is at the borderline of the 
approval limit. In the next stability point, the drug would 
likely be disapproved. Given that the shelf-life declared in 
the package of the medicine is 2 years, it can be questioned 
whether a patient taking this product close to this time is 
actually consuming a medicine with assured quality and 
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clinical efficiency. Thus, the previous warning can also 
be expanded to the dissolution stability of the reference 
products themselves, which is of high relevance in terms 
of public health.
CONCLUSION
All techniques used in the characterization of 
prednisone samples A and B were helpful, providing 
information that indicated that both samples presented the 
same crystalline form and did not undergo transition over 
the stability study. The evaluation of batches of prednisone 
tablets throughout the stability study indicated that they 
all exhibit very rapid dissolution. Notably, when analysed 
individually, the dissolution profiles of all batches, except 
R023, exhibited minimal variation and remained similar 
during the entire study period. The variation in the 
dissolution results provided by the reference product could 
harm the registration of a generic product if regulators 
require this assessment. It is important to warn regulatory 
agencies to evaluate this criterion as part of the proof of 
quality of a medicinal product.
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